Marinus Pharmaceuticals, Inc.
170 Radnor Corporate Center
100 Matson Rd, Suite 500
Radnor, PA 19087
United States
Tel: 484-801-4674
Website: http://www.marinuspharma.com/
256 articles about Marinus Pharmaceuticals, Inc.
-
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
3/31/2022
Marinus Pharmaceuticals , Inc. today announced it has received $30 million in funding under the existing Oaktree Capital Management, L.P. (Oaktree) credit agreement.
-
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
3/21/2022
Marinus Pharmaceuticals, Inc. today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.
-
Ztalmy is Marinus' oral suspension medication for patients ages two years and older who experience seizures linked with cyclin-dependent kinase-like 5 deficiency disorder.
-
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
3/18/2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved ZTALMY® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD).
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Mar 15, 2022
3/15/2022
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to three new employees.
-
The FDA has a full PDUFA calendar for the second half of March for New Drug Applications and Biologics License Applications. Here's a look.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Marinus Pharmaceuticals reported that its Phase III RAISE trial of IV ganaxolone for status epilepticus will be delayed, thanks to the pandemic.
-
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
2/22/2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the RAISE, Phase 3, double-blind placebo-controlled trial for the treatment of status epilepticus, is now expected to be completed in the second half of 2023.
-
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
2/16/2022
Marinus Pharmaceuticals, Inc. today announced plans to provide a business update and preliminary financial results for the fourth quarter and fiscal year ended December 31, 2021 before the market opens on March 21, 2022.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Feb 10, 2022
2/10/2022
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to six new employees.
-
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
2/3/2022
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Jan 14, 2022
1/14/2022
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.
-
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
1/5/2022
Marinus Pharmaceuticals, Inc. today announced that company management will present virtually during the H.C. Wainwright Bioconnect Conference as well as the 40th Annual J.P. Morgan Healthcare Conference.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Dec 27, 2021
12/27/2021
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.
-
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting
12/3/2021
Marinus Pharmaceuticals, Inc. today announced new clinical trial and research data being presented at the American Epilepsy Society (AES) Annual Meeting in Chicago, Illinois.
-
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
11/22/2021
Marinus Pharmaceuticals, Inc. today announced that nine abstracts highlighting clinical trial and research data have been accepted for poster presentation at the American Epilepsy Society (AES) Annual Meeting being held in Chicago, Illinois, from December 3 through 7, 2021.
-
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Nov 15, 2021
11/15/2021
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced that members of its leadership team will present at the following investor conferences in November and December.
-
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
11/9/2021
Marinus Pharmaceuticals, Inc. today provided an update on its clinical and regulatory development activities and reported its financial results for the third quarter ended September 30, 2021.
-
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 08, 2021
11/8/2021
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.